Agilent Technologies (NYSE:A) Upgraded to Buy at UBS Group

Key Points

• Agilent Technologies received a ratings upgrade from UBS Group from "neutral" to "buy", with a price target of $170.00, suggesting a potential upside of 22.69% from the previous close.
• Analysts from Wells Fargo, Rothschild & Co, and Barclays have also raised their price targets for Agilent, collectively indicating strong positive sentiment toward the stock.
• The company's latest quarterly earnings report revealed a 10.1% year-over-year increase in revenue, with EPS matching estimates at $1.37.

Agilent Technologies (NYSE:A - Get Free Report) was upgraded by investment analysts at UBS Group from a "neutral" rating to a "buy" rating in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage presently has a $170.00 price target on the medical research company's stock. UBS Group's price target would indicate a potential upside of 22.69% from the company's previous close.

A number of other analysts have also recently weighed in on the company. Wells Fargo & Company raised their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a research report on Monday, September 15th. Rothschild & Co Redburn assumed coverage on Agilent Technologies in a research note on Wednesday. They set a "buy" rating and a $165.00 price target on the stock. Evercore ISI boosted their price target on Agilent Technologies from $128.00 to $140.00 and gave the company an "in-line" rating in a research note on Tuesday. Weiss Ratings reiterated a "hold (c)" rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Finally, Barclays boosted their price target on Agilent Technologies from $125.00 to $150.00 and gave the company an "equal weight" rating in a research note on Thursday, October 2nd. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Agilent Technologies currently has an average rating of "Moderate Buy" and an average price target of $147.92.

Agilent Technologies Trading Down 2.2%

Shares of NYSE A opened at $138.56 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The business's 50 day moving average price is $123.61 and its 200-day moving average price is $116.64. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a market cap of $39.28 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 4.62 and a beta of 1.26.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies's quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the business posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, sell-side analysts expect that Agilent Technologies will post 5.58 earnings per share for the current year.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after purchasing an additional 4,362 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after acquiring an additional 2,371 shares during the last quarter. Alps Advisors Inc. lifted its holdings in Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after acquiring an additional 3,040 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after acquiring an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. lifted its holdings in Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after acquiring an additional 54,302 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.